↓ Skip to main content

Oncotarget

A phase II study of axalimogene filolisbac for patients with previously treated, unresectable, persistent/recurrent loco-regional or metastatic anal cancer

Overview of attention for article published in Oncotarget, April 2020
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (73rd percentile)
  • Above-average Attention Score compared to outputs of the same age and source (59th percentile)

Mentioned by

twitter
11 X users

Citations

dimensions_citation
19 Dimensions

Readers on

mendeley
14 Mendeley